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Abstract 
Background: Poor graft function (PGF) is a life‑threatening complication after allogeneic hematopoietic stem cell 
transplantation (allo‑HSCT). Nevertheless, whether abnormalities of T cell subsets in the bone marrow (BM) immune 
microenvironment, including Th17, Tc17, Th1, Tc1, Th2, Tc2 cells and regulatory T cells (Tregs), are involved in the 
pathogenesis of PGF remains unclear.
Methods: This prospective nested case–control study enrolled 20 patients with PGF, 40 matched patients with good 
graft function (GGF) after allo‑HSCT, and 20 healthy donors (HD). Th17, Tc17, Th1, Tc1, Th2, Tc2 cells, Tregs and their 
subsets were analyzed by flow cytometry.
Results: A significantly higher proportion of stimulated CD4+ and CD8+ T cells that produced IL‑17 (Th17 and Tc17) 
was found in the BM of PGF patients than in the BM of GGF patients and HD, whereas the percentages of Tregs in PGF 
patients were comparable to those in GGF patients and HD, resulting in a dramatically elevated ratio of Th17 cells/
Tregs in the BM of PGF patients relative to those in GGF patients. Moreover, both CD4+ and CD8+ T cells were polar‑
ized towards a type 1 immune response in the BM of PGF patients.
Conclusions: The present study revealed that aberrant T cell responses in the BM immune microenvironment may 
be involved in the pathogenesis of PGF after allo‑HSCT. These findings will facilitate the optimization of immune regu‑
lation strategies and improve the outcome of PGF patients post‑allotransplant.
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Background
Poor graft function (PGF) remains a life-threatening 
complication following allogeneic hematopoietic stem 
cell transplantation (allo-HSCT), and the underlying 
mechanisms have not yet been elucidated [1–3]. Consid-
erable evidence from murine studies has demonstrated 
that effective hematopoiesis depends on the specific 
bone marrow (BM) microenvironment, where hemat-
opoietic stem cells (HSCs) reside [4–6]. BM endosteal 
cells, endothelial progenitor cells (EPCs), and perivascu-
lar cells have been regarded as the preferential elements 
that support hematopoiesis in the BM microenviron-
ment [7, 8]. In this regard, we recently reported that 
even if the CD34+ BM cells from transplanted donors 
are functionally normal pre-transplant, reactive oxygen 
species-induced apoptosis may contribute to the exhaus-
tion of CD34+ BM cells in patients with PGF following 
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defective BM EPCs, endosteal cells, and perivascular 
cells in the BM microenvironment [10, 11]. Moreover, 
atorvastatin may improve the ability of impaired BM 
EPCs to support HSCs in PGF patients, although these 
findings were not statistically significant, as determined 
by colony-forming unit plating efficiency in  vitro [12]. 
Together, these data appear to suggest that the impaired 
BM microenvironment may hamper the hematopoietic 
reconstitution of successfully engrafted donor HSCs, ulti-
mately leading to the occurrence of PGF post-allo-HSCT.
In addition to the aforementioned elements of the 
BM microenvironment, various mature immune cell 
types, including T cells, B cells, dendritic cells, and mac-
rophages, constitute the BM immune microenvironment 
and regulate the process of hematopoiesis [13, 14]. Clini-
cal data and murine studies have shown that aberrant T 
cell responses in the BM microenvironment may exac-
erbate cytopenia and the dysfunction of HSCs and EPCs 
[15, 16]. Although the enrolled numbers of patients with 
PGF (N  =  10) or good graft function (GGF) (N  =  20) 
were limited, our pilot study found that both CD4+ and 
CD8+ T cells were polarized towards a type 1 immune 
response in the BM microenvironment of PGF patients 
compared to those in matched GGF patients [17]. 
However, the pattern of other T cell subsets in the BM 
immune microenvironment of PGF patients remains to 
be explored.
In addition to Th1 and Th2 cells, Th17 cells are an 
independent helper T cell lineage that is characterized 
by the production of interleukin (IL)-17 [18]. It has been 
determined that Th17 cells play a role in inflammation 
and autoimmune disease [19, 20]. CD4+CD25+CD127−/
low regulatory T cells (Tregs), which express the fork-
head transcription factor Foxp3, are considered a group 
of suppressor T cells that are key players in the regula-
tion of immune responses [21]. Th17 cells and Tregs are 
reciprocally related to each other. For example, TGF-β 
alone induces Treg differentiation, whereas Th17 differ-
entiation is induced by TGF-β in combination with IL-6 
and IL-21 [22]. The balance between Th17 cells and Tregs 
may shift towards IL-17-dominated pro-inflammatory 
responses during infection, autoimmune disease and 
graft-versus-host disease (GvHD) [23–26]. Th17 cells and 
Tregs also exist in the BM immune microenvironment 
and participate in the regulation of hematopoiesis [15, 16, 
27]. However, less is known about Th17 cells and Tregs in 
the BM immune microenvironment of PGF patients.
Therefore, a prospective nested case–control study was 
conducted to evaluate whether the Th17, Tc17, Th1, Tc1, 
Th2, Tc2 cells, Tregs and their subsets in the BM immune 
microenvironment in allo-HSCT patients with PGF dif-
fer from those in patients with GGF or in healthy donors 
(HD). The aim of the current study was to provide new 




Twenty patients who had developed PGF after allo-
HSCT were enrolled in this prospective nested case–
control study. These cases were identified from patients 
who underwent allo-HSCT for hematological dis-
eases between February 1, 2015 and January 31, 2016 
at Peking University Institute of Hematology and were 
enrolled according to the following criteria: age at HSCT 
(±1  years), underlying disease, pre-HSCT cycles of 
chemotherapy (±1 cycle), and disease status at HSCT 
(“risk-set sampling”) [28]. Two matched GGF patients 
(n = 40) for each PGF case were randomly selected from 
the same cohort at the time PGF occurred. Among them, 
10 patients with PGF and 20 matched GGF patients had 
been partially reported [17]. BM samples from 12 male 
and 8 female HD were used as healthy controls. The age 
of the HD ranged from 19 to 51 years (median: 39 years). 
This study was approved by the Ethics Committee of 
Peking University People’s Hospital. Informed consent 
was obtained from all patients and donors before entry 
into the study in accordance with the Declaration of 
Helsinki.
Transplantation protocols
Donor selection, HLA typing, graft harvesting, condi-
tioning therapy and GvHD prophylaxis were performed 
as previously reported [10, 29–32]. The subjects were 
screened for cytomegalovirus (CMV) infection by serol-
ogy. Real-time quantitative PCR was used to detect 
CMV reactivation twice a week in blood samples. CMV 
infection was treated with ganciclovir or foscarnet as 
described [33]. After allo-HSCT, recombinant human 
granulocyte colony-stimulating factor (rhG-CSF) (5  μg/
kg/day) was administered to the recipients of HLA-mis-
matched related transplants from day +6 until the neu-
trophil level was >0.5  ×  109/L for 3 consecutive days. 
rhG-CSF was not administered to recipients of HLA-
identical sibling transplants, except in cases where neu-
trophil levels were <0.5 × 109/L until day +21.
Definition of good/poor graft function
Transplant recipients had to have complete donor 
hematological chimerism with no residual or recurrent 
leukemia. Good graft function [9–12, 17, 34] was char-
acterized by an absolute neutrophil cell (ANC) count 
>0.5  ×  109/L for 3 consecutive days, platelet (PLT) 
count >20  ×  109/L for 7 consecutive days, and hemo-
globin (Hb) level >70  g/L without transfusion support 
beyond day +28 post-HSCT. Poor graft function [9–12, 
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17] was defined as a hypo- or aplastic BM with 2 or 3 of 
the following characteristics: (1) ANC  ≤  0.5  ×  109/L; 
(2) PLT  ≤  20  ×  109/L; and/or (3) hemoglobin concen-
tration ≤70 g/L for at least 3 consecutive days after day 
+28 post-HSCT or in accordance with platelet and/or 
red blood cell (RBC) transfusion and/or G-CSF support 
requirement. All RBC and PLT transfused to the patients 
post-HSCT were gamma irradiated. Patients with evi-
dence of severe GvHD including III-IV acute GvHD and 
severe chronic GvHD or hematologic relapse after allo-
HSCT were excluded.
Chimerism analyses were conducted using DNA fin-
gerprinting for short tandem repeats (STRs) in blood 
samples and/or chromosome fluorescent in situ hybridi-
zation of bone marrow samples. Complete donor chi-
merism was defined as the detection of no recipient 
hematopoietic or lymphoid cells (sensitivity >0.1% recipi-
ent signals) [32].
Surface immunophenotype analysis of T cell subsets
Bone marrow mononuclear cells (BMMNCs) were sepa-
rated using Lymphocyte Separation Medium (HaoYang, 
Tianjin, China). Lymphocyte subsets were quantified by 
flow cytometry using the following directly conjugated 
mouse anti-human monoclonal antibodies: V500-con-
jugated anti-CD3, PerCP-conjugated anti-CD4, APC-
conjugated anti-CD45RA, and PE-conjugated anti-CCR7 
(BD Biosciences, San Jose, CA). After incubation, RBCs 
were lysed, and white blood cells (WBCs) were fixed with 
a lysing solution (BD Biosciences). As previously reported 
[17, 25, 35], effector T cells, naïve T cells, effector mem-
ory T cells, and central memory T cells were identified as 
CD45RA+CCR7−, CD45RA+CCR7+, CD45RA−CCR7−, 
and CD45RA−CCR7+, respectively. Multi-parameter 
flow cytometric analyses were performed using a BD 
LSRFortessa (Becton–Dickinson). Data were analyzed 
using BD Diva software (Becton–Dickinson).
Intracellular cytokine staining
Intracellular cytokine secretions were measured by 
flow cytometry after incubating the cells with phorbol 
myristate acetate (100  ng/mL; Sigma, St. Louis, MO, 
USA) and ionomycin (2  μg/mL Sigma, St. Louis, MO, 
USA) for 4 h to stimulate maximal IFN-γ, IL-4 and IL-17 
production. GolgiStop (0.7  μL/mL) was added to the 
samples during this 4-h incubation to sequester pro-
teins in the cytoplasm. The monoclonal antibodies APC-
H7-conjugated anti-CD3, PE-conjugated anti-IL-4 (BD 
Biosciences), eFluor450-conjugated anti-CD8, PE-Cy7-
conjugated anti-CD25, PerCP-Cy5.5-conjugated anti-
IFN-γ, eFluor660-conjugated anti-Foxp3 and Alexa Fluor 
488-conjugated anti-IL-17A (eBioscience, San Diego, 
CA, USA) were used to distinguish cell surface markers 
and intracellular cytokines. The typical gating strat-
egies for the different T cell subsets in the BM of PGF, 
GGF, and HD are shown in Fig.  1. CD3+CD8−IFN-γ+, 
CD3+CD8−IL-4+, CD3+CD8−IL-17A+, and 
CD3+CD8−CD25+Foxp3+ cells were defined as Th1, Th2, 
Th17 cells and Tregs, respectively. Tc1, Tc2 and Tc17 cells 
were identified as CD3+CD8+IFN-γ+ CD3+CD8+IL-4+, 
and CD3+CD8+IL-17A+, respectively. For Treg sub-
sets analyses, CD4+CD25+CD127−/dimCD45RA+HLA-
DR−, CD4+CD25+CD127−/dimCD45RA−HLA-DR−, 
and CD4+CD25+CD127−/dimCD45RA−HLA-DR+ cells 
were further defined as naïve Tregs, memory Tregs and 
active Tregs [36], respectively. For the definition of other 
Treg subsets, CD45RA+CD25dim, CD45RA−CD25high, 
and CD45RA−CD25dim represented resting Tregs, active 
Tregs and nonsuppressive Tregs [37], respectively. Per-
centages of cytokine-producing cells were calculated 
using overall CD4+ or CD8+ T cell subpopulations rather 
than total T cell populations. Type 1/type 2 ratios were 
calculated using the percentage of IFN-γ-producing 
cells divided by the percentage of IL-4-producing cells, 
whereas the ratio of Th17 cells/Tregs was calculated as 
the percentage of IL-17-producing cells divided by the 
percentage of CD25+Foxp3+ T cells.
Statistical analysis
Median values and ranges are reported for continuous 
variables, and proportions are reported for categori-
cal variables. Characteristics of the patients in the PGF 
and GGF groups were compared using the Chi square 
test for categorical variables and the Mann–Whitney U 
test for continuous variables. Analyses were performed 
using GraphPad Prism 6.0 (GraphPad Software, La Jolla, 




This prospective nested case–control study enrolled 20 
patients with PGF, 40 matched patients with GGF after 
allo-HSCT and 20 HD. As shown in Table  1, PGF and 
GGF patients had their BM microenvironment tested at 
a matched median time point after allo-HSCT (102 days 
vs. 92.5 days, P = 0.14) to minimize the potential influ-
ence of the length of time after allo-HSCT. Additionally, 
polymerase chain reaction DNA fingerprinting of the 
STRs of the recipient peripheral blood showed complete 
donor chimerism in all patients.
The demographic and clinical characteristics of PGF 
and GGF patients, including age, gender, underlying dis-
ease, disease status pre-HSCT, median time from diag-
nosis to HSCT, source of stem cells, transplanted total 
nucleated cell dose, CD34+ cell dose, donor HLA match, 
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sex/ABO mismatch, pre-HSCT cycles of chemotherapy, 
preparative regimens, GvHD prophylaxis and history of 
GvHD and CMV status, were comparable (Table 1).
Blood and BM cellularity
The hemograms of PGF patients showed significant pan-
cytopenia compared with those of GGF patients. The 
median WBC (1.1 × 109/L vs. 5.0 × 109/L, P < 0.0001), 
ANC (0.7  ×  109/L vs. 2.6  ×  109/L, P  =  0.0007), Hb 
(83 g/L vs. 114.5 g/L, P < 0.0001) and PLT (29 × 109/L vs. 
149.5 × 109/L, P < 0.0001) levels in the PGF group were 
dramatically lower than those of the GGF group when the 
BM was evaluated (Table  1). The BMMNCs in the PGF 
group were significantly reduced compared with those 
in the GGF group (Fig.  2; 0.8  ×  109/L vs. 2.6  ×  109/L, 
P < 0.0001).
Lymphocyte subsets in BMMNCs
The median percentages and absolute quantities of T 
lymphocyte subpopulations in BMMNCs from PGF 
patients, GGF patients, and HD are provided in Addi-
tional file  1: Table  S1. Conspicuous lymphopenia was 
exhibited in the PGF group. Lymphocyte percentages in 
the PGF and GGF group were slightly lower than those 
in the HD group. Thus, the observed lymphopenia was 
primarily caused by an overall reduction in the absolute 
values of T lymphocyte subgroups in BMMNCs, and 
the subtle decrease in lymphocyte percentage may have 
Fig. 1 The lymphocyte population was initially defined using forward (FSC) and side scatter (SSC) gates. CD4+ T cells and CD8+ T cells were then 
gated based on CD4 and CD8 expression, respectively. a Representative flow cytometric analyses of CD25+CD127−/dim Tregs and CD45RA+HLA‑
DR− naïve Tregs from PGF patients, GGF patients, and HD. b Representative flow cytometric analyses of CD4+IL‑17+ Th17, CD8+IL‑17+ Tc17 cells, 
and CD25+Foxp3+ Tregs from PGF patients, GGF patients, and HD
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Table 1 Characteristics of allo-HSCT patients with PGF and GGF
allo-HSCT allogeneic haematopoietic stem cell transplantation, PGF poor graft function, GGF good graft function, AML acute myelogenous leukemia, ALL acute 
lymphocytic leukemia, CML chronic myelogenous leukemia, MDS myelodysplastic syndrome, sAA sever aplastic anemia, HLA human leukocyte antigen, BU busulfan, 
CY cyclophosphamide; ATG anti-human thymus globulin; aGvHD acute graft-versus-host disease, CMV cytomegalovirus
* Group matching criteria included age at HSCT (±1 years), pre-HSCT cycles of chemotherapy (±1 cycle), disease status at HSCT and BM microenvironment evaluated 
time after HSCT (±5 days). For each PGF case, two GGF control was randomly selected from the same cohort at which the PGF occurred (“risk-set sampling”)
** The continuous variables were compared using the Mann–Whitney U test, and the differences in frequency between the 2 groups were compared using the Chi 
square test. The criterion for statistical significance was P < 0.05
Characteristics PGF* (n = 20) GGF* (n = 40) P value**
BM evaluated time (post‑HSCT days) 102 (53–152) 92.5 (24–561) 0.14
Blood cell count
 Median WBC (×109/L) (range) 1.1 (0.3–2.7) 5.01 (1.93–9.83) <0.0001
 Median ANC (×109/L) (range) 0.7 (0.1–1.8) 2.62 (0.84–7.1) 0.0007
 Median Hb (g/L) (range) 83 (68–104) 114.5 (85–165) <0.0001
 Median PLT (×109/L) (range) 29 (4–53) 149.5 (31–266) <0.0001
Age at HSCT (years, median, range) 33.5 (11–62) 26 (7–51) 0.10
Gender (male/female) 15/5 24/16 0.39
Underlying disease 0.78
 AML 6 14
 ALL 9 16
 CML 0 2
 MDS 3 4
 sAA 2 4
Status at HSCT 0.54
 Standard‑risk 4 12
 High‑risk 16 24
Source of stem cell 0.99
 BM and G‑PB 19 38
 G‑PB 1 2
Transplanted total nucleated cell dose (×108/kg, median, range) 8.08 (6.01–14.49) 7.615 (5.22–13.81) 0.68
Transplanted CD34+ cell dose (×108/kg, median, dose) 2.29 (1.18–0.5.28) 2.49 (0.85–6) 0.09
Donor match 0.34
 HLA‑identical unrelated donor 1 2
 HLA‑identical sibling donor 3 12
 HLA‑partially matched related 16 26
Sex mismatch 0.99
 Female to male 5 9
 Female to female 2 2
 Male to female 4 13
 Male to male 9 16
ABO mismatch 0.47
 No 12 26
 Minor 3 6
 Major 5 8
Pre‑HSCT cycles of chemotherapy 4 (0–6) 3.5 (0–11) 0.86
Conditioning 0.34
 BU/CY 3 12
 BU/CY + ATG 17 28
History of aGvHD 13 21 0.77
History of CMV reactivation 17 24 0.08
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had an influence as well. As shown in Additional file  1: 
Table S1, the median value of absolute counts of lympho-
cytes (0.1 × 109/L vs. 0.5 × 109/L, P < 0.0001), CD4+ T 
cells (0.003  ×  109/L vs. 0.04  ×  109/L, P  <  0.0001), and 
CD8+ T cells (0.01 × 109/L vs. 0.2 × 109/L, P < 0.0001) 
were significantly decreased in PGF patients compared 
with those in GGF patients. The median percentages 
of CD8+ T cells (30.6 vs. 42.6%, P =  0.13) between the 
PGF and GGF groups showed no significant difference, 
whereas the median percentage of CD4+ T cells (3.4 
vs. 8.4%, P =  0.004) was significantly decreased in PGF 
patients.
In terms of the CD4+ and CD8+ subsets, the state of 
activation was evaluated based on the surface expression 
of HLA-DR. As shown in Additional file 1: Table S1, the 
percentage of activated CD8+ T cells and active CD4+ 
T cells in the BM immune microenvironment was sig-
nificantly higher in PGF patients than in GGF patients. 
With the exception of activated CD4+ T cells and CD8+ 
T cells, the absolute quantities of cell subsets were signifi-
cantly lower among PGF patients than among HD. Com-
pared with HD, PGF and GGF patients showed lower 
levels of naïve phenotypes for both CD4+ T cells and 
CD8+ T cells, but higher levels of effector CD8+ T cells. 
In addition, the percentages of effector memory CD4+ 
T cells and effector memory CD8+ T cells were elevated 
PGF and GGF patients compared with HD.
Increased expression of Th17, Tc17, Th1, and Tc1 cells in the 
BM of PGF patients
We first analyzed the frequency of Th17 cells, Tc17 cells 
and Tregs in PGF patients, GGF patients and HD. A 
representative dot plot of the percentages of Th17 cells, 
Tc17 cells and Tregs in representative PGF patients, GGF 
patients and HD is shown in Fig.  1. The percentages of 
Th1, Th2 and Th17 cells among CD4+ T cells and the per-
centages of Tc1, Tc2 and Tc17 cells among CD8+ T cells 
are shown in Fig. 3. The percentages of Th1 (37 vs. 26.4%, 
P = 0.0005) and Tc1 (52.4 vs. 19%, P < 0.0001) cells were 
significantly higher in PGF patients than in GGF patients, 
whereas the percentages of Th2 (0.8 vs. 2.4%, P < 0.0001) 
and Tc2 (0.5 vs. 1.1%, P  <  0.0001) cells were markedly 
lower in PGF group than in GGF group. The median 
percentages of Th1 (26.4 vs. 18.5%, P = 0.05), Tc1 (19 vs. 
23.6%, P =  0.81), and Th2 cells (2.4 vs. 1.8%, P =  0.11) 
showed no significant differences between GGF group 
Fig. 2 The absolute numbers of BMMNCs (a), lymphocytes (d), CD4+ T cells (e) and CD8+ T cells (f). The percentages of CD4+ T cells (b) and CD8+ T 
cells (c). Statistical analyses were performed using the Mann–Whitney U test. *P values < 0.05; **P values < 0.005; ***P values < 0.0001
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and HD group, whereas the percentage of Tc2 cells (1.1 
vs. 1.5%, P = 0.04) in GGF group was lower than that in 
HD group.
The type 1/type 2 immune response ratio was calcu-
lated using the Th1 cell/Th2 cell and Tc1 cell/Tc2 cell 
ratios. PGF patients showed significantly greater median 
Th1 cell/Th2 cell ratio (31.6 vs. 10.8, P < 0.0001) and Tc1 
cell/Tc2 cell ratio (108.8 vs. 18.4, P < 0.0001) than those 
for GGF patients, whereas similar Th1 cell/Th2 cell ratio 
(10.8 vs. 8, P = 0.71) and Tc1 cell/Tc2 cell ratio (18.4 vs. 
14.8, P  =  0.22) were found between GGF patients and 
HD.
We also evaluated the surface phenotypes of Tregs 
(Additional file  1: Figure S1). The percentages of 
CD45RA−HLA-DR+ active Tregs (61.2 vs. 51 vs. 18.0%, 
P < 0.05) were higher in PGF and GGF patients than HD, 
whereas the percentages of CD45RA+HLA-DR− naïve 
Tregs were lower in PGF and GGF patients than in HD 
(1.1 vs. 2.9 vs. 24.9%, P  <  0.05). Tregs were defined as 
CD4+CD25+Foxp3+ T cells after intracellular staining. 
The proportions of CD4+CD25+Foxp3+ Tregs among 
PGF patients, GGF patients and HD were comparable 
(Fig. 3, 4.5 vs. 2.8 vs. 3.3%, P > 0.05), and the percentages 
of CD4+CD25+CD127−/dim Tregs showed no significant 
difference among patients with PGF, GGF and HD (Addi-
tional file 1: Figure S1). Compared to HD, the percentages 
of the resting Tregs were lower, whereas the percentages 
of active and nonsuppressive Tregs were higher in PGF 
and GGF patients (Additional file 1: Figure S1).
The proportions of Tregs among CD4+ T cells were 
comparable between PGF patients, GGF patients and 
HD. There was a significantly elevated percentage of 
Th17 cells in PGF patients compared with the per-
centage in GGF patients and HD (3.7 vs. 1.6 vs. 1.1%, 
P  <  0.05). Consequently, a prominent increase in the 
Th17 cell/Treg ratio was observed in PGF group com-
pared with the ratio in GGF and HD groups (1.0 vs. 0.6, 
P =  0.04), whereas similar Th17 cell/Treg ratio (0.6 vs. 
0.4, P = 0.09) was observed between GGF group and HD 
group (Fig. 3).
Fig. 3 The percentages of the Th1 cell (a), Th2 cell (b), Th17 cell (g) and Treg (h) subsets among CD4+ T cells and the percentages of the Tc1 (d), 
and Tc2 (e) cell subsets among CD8+ T cells. Th1 cell/Th2 cell (c), Tc1 cell/Tc2 cell (f) and Th17 cell/Treg (i) ratios. Statistical analyses were performed 
using the Mann–Whitney U test
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Discussion
In this nested case–control study, we demonstrated that 
PGF patients had a significantly higher proportion of 
stimulated CD4+ and CD8+ T cells that produced IL-17 
(Th17 and Tc17), resulting in an IL-17-dominant response, 
whereas the proportions of Tregs among CD4+ T cells 
showed no significant differences between PGF and GGF 
patients. Therefore, a prominent increase in the Th17 cell/
Treg ratio was observed in PGF patients compared with 
that of GGF patients. Additionally, we confirmed that both 
CD4+ and CD8+ T cells were polarized towards a type 1 
immune response in PGF patients [17]. However, no signif-
icant different Th1 cell/Th2 cell, Tc1 cell/Tc2 cell and Th17 
cell/Treg ratios were found between GGF patients and HD. 
These data suggest that dysregulated T cell responses may 
contribute to the occurrence of PGF post-allo-HSCT.
Rapid and persistent hematopoietic recovery plays a 
predominant role in successful allo-HSCT. Growing evi-
dence suggests that BM-resident T cells may contribute 
to the formation of the perivascular BM immune micro-
environment and participate in the regulation of hemat-
opoiesis [13–16]. The Th1 cell/Th2 cell balance is well 
known to regulate the immune system under normal 
situations, whereas Th1 cell/Th2 cell imbalances have 
been reported in aplastic anemia (AA) and autoimmune 
diseases [38, 39]. The Th1 cell polarization of the immune 
response was reported in immune thrombocytopenia 
(ITP) in vitro [40] as well as in the BM immune microen-
vironment of ITP patients [25]. Moreover, our previous 
pilot study demonstrated an increased type 1 immune 
response in the BM immune microenvironment of PGF 
patients after allo-HSCT [17]. By enlarging the sample 
size, the current nested case–control study confirmed 
that both CD4+ and CD8+ T cells were polarized towards 
a type 1 immune response in PGF patients. Thus, it is 
plausible that deficits in the BM microenvironment due 
to aberrant immune responses by these CD4+ and CD8+ 
T cells may aggravate BM dysfunction.
Several groups have shown that Th17/Tc17 cells con-
tribute to the pathogenesis of inflammation, autoimmune 
disease, tumors and hematopoiesis [41–43]. De Latour 
et al. [41]. reported an increased frequency of Th17 cells 
among BMMNCs and peripheral blood mononuclear cells 
in 41 patients with severe AA before any specific therapy 
at diagnosis, along with a reduction in Tregs. Evidence 
from a murine study showed that Th17 cells impact cell 
fate and function via the mTOR signaling pathway and 
metabolic processes [44]. In the current study, the propor-
tions of Th17 and Tc17 cells were found to be significantly 
increased in the BM microenvironment of PGF patients 
compared with the proportions in GGF patients. These 
findings may indicate a very important role for Th17 and 
Tc17 cells in regulating HSCs recovery after allo-HSCT.
Tregs represent one-third of all CD4+ T cells in the 
BM microenvironment [27]. It has been shown in  vitro 
that Treg defects may contribute to impaired hemat-
opoiesis mediated by effector T cells in acquired AA, and 
increased autoreactive T cells may promote the develop-
ment of AA [45, 46]. In mouse transplantation models, 
allogeneic HSCs have been reported to protect against 
allorejection by host Tregs, which raises the possibility 
that Tregs contribute to maintaining immune-privileged 
sites [27]. However, no significant differences were found 
in the percentages of Tregs between the PGF and GGF 
groups, whereas a prominent increase in the Th17 cell/
Treg ratio was observed in PGF patients compared with 
GGF patients.
Aberrant T cell responses, including both CD4+ 
and CD8+ T cells, polarized towards a type 1 immune 
response as well as a Th17 cell/Treg imbalance were 
found in the BM immune microenvironment of PGF 
patients. Considering the crucial role of the BM immune 
microenvironment in supporting hematopoiesis [13–16], 
we hypothesize that a dysregulated BM immune micro-
environment may hamper the hematopoietic reconsti-
tution of successfully engrafted donor HSCs, ultimately 
leading to the occurrence of PGF post-allotransplant.
We are aware, however, that additional functional 
studies are required to illuminate the direct interac-
tions between the dysregulated immune cells and HSCs 
or other cellular elements of the BM microenviron-
ment, as well as the molecular mechanisms underlying 
this phenomenon. Moreover, although the RBC and PLT 
transfused to the patients post-HSCT were gamma irra-
diated, future studies are needed to elucidate whether the 
increased number of CD8+ effector cells in PGF patients 
are due to responses resulting from the transfusion.
Conclusions
In conclusion, the present study revealed that imbalances 
in the Th1 cell/Th2 cell, Tc1 cell/Tc2 cell, and Th17 cell/
Treg ratios in the BM immune microenvironment of PGF 
patients compared with GGF patients. Although requir-
ing further validation, these data suggest that aberrant 
T cell responses in the BM immune microenvironment 
appear to be involved in the occurrence of PGF. There-
fore, it would be of value to investigate whether poten-
tial immunotherapy targeting aberrant T cell responses 
could improve hematopoietic reconstitution by correct-
ing the impaired BM immune microenvironment in PGF 
patients post-allotransplant in the future.
Additional file
Additional file 1. Distribution of the T lymphocyte subsets in bone mar‑
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